argenx SE (ARGX)
605.92
+9.18
(+1.54%)
USD |
NASDAQ |
Nov 22, 16:00
597.01
-8.91
(-1.47%)
After-Hours: 20:00
argenx Enterprise Value: 33.13B for Nov. 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 22, 2024 | 33.13B |
| November 21, 2024 | 32.58B |
| November 20, 2024 | 32.29B |
| November 19, 2024 | 31.25B |
| November 18, 2024 | 30.86B |
| November 15, 2024 | 30.64B |
| November 14, 2024 | 32.48B |
| November 13, 2024 | 32.74B |
| November 12, 2024 | 32.41B |
| November 11, 2024 | 32.11B |
| November 08, 2024 | 32.54B |
| November 07, 2024 | 32.26B |
| November 06, 2024 | 32.12B |
| November 05, 2024 | 32.92B |
| November 04, 2024 | 32.10B |
| November 01, 2024 | 32.51B |
| October 31, 2024 | 31.96B |
| October 30, 2024 | 29.89B |
| October 29, 2024 | 29.96B |
| October 28, 2024 | 30.05B |
| October 25, 2024 | 30.19B |
| October 24, 2024 | 29.85B |
| October 23, 2024 | 30.26B |
| October 22, 2024 | 30.89B |
| October 21, 2024 | 30.41B |
| Date | Value |
|---|---|
| October 18, 2024 | 30.68B |
| October 17, 2024 | 29.42B |
| October 16, 2024 | 29.22B |
| October 15, 2024 | 29.47B |
| October 14, 2024 | 29.40B |
| October 11, 2024 | 28.99B |
| October 10, 2024 | 28.43B |
| October 09, 2024 | 28.02B |
| October 08, 2024 | 28.42B |
| October 07, 2024 | 28.16B |
| October 04, 2024 | 28.59B |
| October 03, 2024 | 29.37B |
| October 02, 2024 | 29.79B |
| October 01, 2024 | 29.62B |
| September 30, 2024 | 29.31B |
| September 27, 2024 | 28.96B |
| September 26, 2024 | 28.27B |
| September 25, 2024 | 29.73B |
| September 24, 2024 | 27.98B |
| September 23, 2024 | 28.50B |
| September 20, 2024 | 28.77B |
| September 19, 2024 | 28.97B |
| September 18, 2024 | 28.53B |
| September 17, 2024 | 28.12B |
| September 16, 2024 | 29.06B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
3.156B
Minimum
Mar 16 2020
33.13B
Maximum
Nov 22 2024
16.28B
Average
15.80B
Median
Jan 03 2022
Enterprise Value Benchmarks
| Biodexa Pharmaceuticals PLC | -3.256M |
| uniQure NV | -102.39M |
| ProQR Therapeutics NV | 288.57M |
| Akari Therapeutics PLC | 30.94M |
| Merus NV | 2.482B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 91.41M |
| Revenue (Quarterly) | 573.24M |
| Total Expenses (Quarterly) | 557.07M |
| EPS Diluted (Quarterly) | 1.39 |
| Gross Profit Margin (Quarterly) | 89.70% |
| Profit Margin (Quarterly) | 15.95% |
| Earnings Yield | -0.14% |
| Normalized Earnings Yield | -0.26 |